Antibacterial Efficacy of a Hydrogel Formulation using Saururus cernuus
Zenodo (CERN European Organization for Nuclear Research) · 09.08.2023
DOI: 10.5282/pexacy.8227776 ↗Kurz gefasst
Fachartikel in der Zeitschrift Zenodo (CERN European Organization for Nuclear Research), erschienen am 09.08.2023. Verfasst von Anushka Verma und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Antibacterial resistance has become a pressing global health concern, necessitating the exploration of alternative therapeutic agents. This study delved into the potential of Saururus cernuus, a traditionally acknowledged medicinal plant, in a hydrogel formulation, to combat bacterial infections. Four distinct hydrogel formulations were prepared and meticulously evaluated based on various parameters, including pH, viscosity, spreadability, in vitro drug release, and, most crucially, antibacterial activity. The results showcased that all formulations, especially F4, exhibited favorable characteristics for topical application. Remarkably, the antibacterial tests revealed substantial inhibition zones against both Staphylococcus aureus and Escherichia coli. This study underscores the potential of integrating traditional herbal knowledge with contemporary pharmaceutical approaches to combat the challenge of antibiotic resistance.
Schlagwörter
Zitieren
APA
Verma, A., Nigam, P., & rahmath, S. (2023). Antibacterial Efficacy of a Hydrogel Formulation using Saururus cernuus. Zenodo (CERN European Organization for Nuclear Research). https://doi.org/10.5282/pexacy.8227776
Vancouver
Verma A, Nigam P, rahmath S. Antibacterial Efficacy of a Hydrogel Formulation using Saururus cernuus. Zenodo (CERN European Organization for Nuclear Research). 2023. doi:10.5282/pexacy.8227776
BibTeX
@article{Verma2023,
author = {Verma, Anushka and Nigam, Parul and rahmath, Samah},
title = {Antibacterial Efficacy of a Hydrogel Formulation using Saururus cernuus},
journal = {Zenodo (CERN European Organization for Nuclear Research)},
year = {2023},
doi = {10.5282/pexacy.8227776}
}
EUVIMED